Monte Rosa Therapeutics, Inc. (GLUE)
| Previous Close | 5.94 |
| Open | 5.93 |
| Bid | 5.48 x 100 |
| Ask | 6.91 x 200 |
| Day's Range | 5.40 - 5.93 |
| 52 Week Range | 2.44 - 8.84 |
| Volume | |
| Avg. Volume | 137,065 |
| Market Cap | 275.848M |
| Beta (5Y Monthly) | 1.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; program on track with determination of recommended Phase 2 dose expected in Q2 2024 MRT-6160, a VAV1-directed MGD designed to treat systemic and neurological autoimmune diseases, progressing toward expected IND submission in Q2 2024 and initiation of Phase 1 SAD/MAD study midyear MRT-8102 nominated as first development candidate for NEK7 program, targeting disease
- GlobeNewswire
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
MRT-8102 nominated as first NEK7-directed development candidate, targeting inflammatory diseases driven by IL-1β and the NLRP3 inflammasome MRT-8102 and other NEK7 program MGDs are potentially applicable across a range of inflammatory disorders, metabolic disorders, as well as ocular and neurological diseases IND-enabling studies ongoing; IND submission anticipated in Q1 2025 BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology c
- GlobeNewswire
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Guggenheim 6th Annual Biotechnology Conference (New York, NY) – Markus Warmuth, M.D., Chief Executive Officer, to participate in fireside chat, February 7, 2024, at 1:30 p.m. ET.TD Cowen 44th Annual Health Care Conference (Bost
